Scarica l'app Stockscreener
74.79
0.45%
-0.34
Dopo l'orario di chiusura:
74.79
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
IONS PE Ratio & Valuation, Is IONS Overvalued - intellectia.ai
IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC - MarketBeat
Retinitis Pigmentosa Market to Reach US$ 26.2 Billion by 2032 - openPR.com
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - GuruFocus
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Devers, Ionis Pharmaceuticals EVP, sells $458,613 in IONS stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares - MarketBeat
J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
ETF Watch: Can Ionis Pharmaceuticals Inc weather a recessionWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Form 144 | Ionis Pharmaceuticals(IONS.US) Director Proposes to Sell 5.47 Million in Common Stocks - Moomoo
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen - Sahm
FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story - Yahoo Finance
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? - Yahoo Finance
Vanguard disaggregates holdings; reports 0 IONS shares (IONS) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Is It Time To Reassess Ionis Pharmaceuticals (IONS) After Its Strong One Year Share Price Run? - Sahm
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Ionis Cuts Tryngolza Price Ahead Of Big New Indication - Citeline News & Insights
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106 - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays - MarketBeat
Barclays Raises Price Target for Ionis Pharmaceuticals (IONS) to $106 | IONS Stock News - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart
What is HC Wainwright's Estimate for IONS FY2027 Earnings? - marketbeat.com
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com Australia
Wolfe Research reiterates Ionis stock rating on pricing strategy - uk.investing.com
Wolfe Research reiterates Ionis stock rating on pricing strategy By Investing.com - Investing.com Australia
Stifel raises Ionis Pharmaceuticals price target on drug pricing - Investing.com
IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat
Oppenheimer raises Ionis Pharmaceuticals price target on pricing move By Investing.com - Investing.com Canada
Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - theglobeandmail.com
Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
Eugene Schneider reports Common Stock sale notices for IONS (NASDAQ: IONS) - Stock Titan
When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - Yahoo Finance
FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):